논문KCI 등재
Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?박준용, Hye Won Lee, Kyung Joo Cho대한면역학회 · Immune Network2020 · 제20권 제1호Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development김은정한국발생생물학회 · 발생과 생식2023 · 제27권 제4호Molecular stratification of hepatocellular carcinoma by metabolic-signaling pathways guides precision im munotherapy and TACE therapyBinghua Li, Decai Yu, Laizhu Zhang, Tianci Luo, Weiwei Hu, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinomaBing Han, Binghua Li, Decai Yu, Jingyuan Wen, Peng Yan, Zhu Xu대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Naoshi Nishida대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular CarcinomaKim Beom Kyung거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제1호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12